Maria Tagliamonte

List of Publications by Year
in descending order

79	1,796	279487	301761
papers	citations	23 h-index	39 g-index

83	83	83	2729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antigen-specific vaccines for cancer treatment. Human Vaccines and Immunotherapeutics, 2014, 10, 3332-3346.	1.4	124
2	Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses. Journal of Virology, 2006, 80, 9134-9143.	1.5	111
3	Challenges in cancer vaccine development for hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 897-903.	1.8	87
4	Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Review of Vaccines, 2011, 10, 1569-1583.	2.0	82
5	Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cellular and Molecular Life Sciences, 2019, 76, 4869-4886.	2.4	81
6	Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation. Journal of Virology, 2005, 79, 7059-7067.	1.5	73
7	Effects of adjuvants on IgG subclasses elicited by virus-like Particles. Journal of Translational Medicine, 2012, 10, 4.	1.8	66
8	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
9	SARS-CoV-2 RNA polymerase as target for antiviral therapy. Journal of Translational Medicine, 2020, 18, 185.	1.8	64
10	Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 2020, 8, 615.	2.1	59
11	Combinatorial immunotherapy strategies for hepatocellular carcinoma. Current Opinion in Immunology, 2016, 39, 103-113.	2.4	52
12	Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. Cancers, 2020, 12, 1049.	1.7	51
13	Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. Journal of Translational Medicine, 2005, 3, 45.	1.8	41
14	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Letters, 2020, 473, 25-32.	3.2	40
15	Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Cancer Research, 2020, 80, 2575-2585.	0.4	39
16	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine, 2011, 29, 4903-4912.	1.7	38
17	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. Cancers, 2019, 11, 1824.	1.7	36
18	Virus-like Particles as Preventive and Therapeutic Cancer Vaccines. Vaccines, 2022, 10, 227.	2.1	36

#	Article	IF	Citations
19	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 1305-1314.	2.0	31
20	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	3.2	31
21	Potentiating cancer vaccine efficacy in liver cancer. OncoImmunology, 2018, 7, e1488564.	2.1	26
22	Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1295-1306.	0.9	24
23	Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. Infectious Agents and Cancer, 2006, 1, 4.	1.2	24
24	Functional characterization of biodegradable nanoparticles as antigen delivery system. Journal of Experimental and Clinical Cancer Research, 2015, 34, 114.	3.5	24
25	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. Journal of Translational Medicine, 2018, 16, 286.	1.8	24
26	HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine, 2011, 29, 4913-4922.	1.7	23
27	Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunology, Immunotherapy, 2017, 66, 103-112.	2.0	23
28	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Scientific Reports, 2016, 6, 29258.	1.6	22
29	Cellular prognostic markers in hepatocellular carcinoma. Future Oncology, 2015, 11, 1591-1598.	1.1	20
30	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).. , 2021, 9, e002694.		19
31	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget, 2018, 9, 3576-3589.	0.8	19
32	HIV Type 1 Subtype A Epidemic in Injecting Drug User (IDU) Communities in Iran. AIDS Research and Human Retroviruses, 2007, 23, 1569-1574.	0.5	18
33	Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. Vaccine, 2010, 28, 6417-6424.	1.7	18
34	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. Journal of Translational Medicine, 2016, 14, 58.	1.8	18
35	Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infectious Agents and Cancer, 2018, 13, 10.	1.2	18
36	Human papillomavirus infection in urine samples from male renal transplant patients. Journal of Medical Virology, 2010, 82, 1179-1185.	2.5	17

#	Article	IF	Citations
37	Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration. Vaccine Journal, 2012, 19, 970-973.	3.2	17
38	Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy. Cancers, 2021, 13, 1999.	1.7	16
39	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
40	Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. Journal of Medical Virology, 2015, 87, 102-111.	2.5	15
41	HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine. Frontiers in Immunology, 2021, 12, 734689.	2.2	15
42	Developments in virus-like particle-based vaccines for HIV. Expert Review of Vaccines, 2013, 12, 119-127.	2.0	14
43	Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology, 2007, 4, 34.	0.9	10
44	Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines, 2015, 3, 544-555.	2.1	10
45	Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy. Journal of Translational Medicine, 2020, 18, 34.	1.8	10
46	Genetic and Phylogenetic Characterization of Structural Genes from Non-B HIV-1 Subtypes in Italy. AIDS Research and Human Retroviruses, 2006, 22, 1045-1051.	0.5	9
47	Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infectious Agents and Cancer, 2008, 3, 13.	1.2	9
48	Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. Journal of Translational Medicine, 2013, 11, 165.	1.8	9
49	Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. New Microbiologica, 2012, 35, 415-27.	0.1	9
50	Development of a stable insect cell line constitutively expressing rotavirus VP2. Virus Research, 2013, 172, 66-74.	1.1	8
51	Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. Journal of Translational Medicine, 2014, 12, 11.	1.8	8
52	Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. Journal of Translational Medicine, 2021, 19, 89.	1.8	8
53	Novel Molecular Targets for Hepatocellular Carcinoma. Cancers, 2022, 14, 140.	1.7	8
54	Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies. Journal of Translational Medicine, 2010, 9, S1.	1.8	7

#	Article	IF	Citations
55	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines, 2020, 8, 41.	2.1	7
56	HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens. PLoS ONE, 2012, 7, e43318.	1.1	6
57	MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response. Frontiers in Immunology, 2021, 12, 769799.	2.2	6
58	Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiologica, 2007, 30, 1-11.	0.1	6
59	Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. Journal of Virological Methods, 2005, 124, 123-134.	1.0	5
60	Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. Cancer Research, 2020, 80, LB-094-LB-094.	0.4	5
61	Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens?. Vaccine Journal, 2011, 18, 2003-2004.	3.2	4
62	Virus-Like Particles. , 2017, , 205-219.		4
63	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. Journal of Translational Medicine, 2021, 19, 526.	1.8	3
64	Systems vaccinology for cancer vaccine development. Expert Review of Vaccines, 2014, 13, 711-719.	2.0	2
65	Chemokine Receptor Interactions with Virus-Like Particles. Methods in Molecular Biology, 2013, 1013, 57-66.	0.4	2
66	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
67	Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients. , 2016, , .		1
68	P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles. Retrovirology, 2009, 6, .	0.9	0
69	P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies. Retrovirology, 2009, 6, .	0.9	0
70	Corrigendum to: â€œChallenges in cancer vaccine development for hepatocellular carcinomaâ€•[J Hepatol 2013;59:897â€“903]. Journal of Hepatology, 2014, 60, 237.	1.8	0
71	High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients. Journal of Hepatology, 2020, 73, S566.	1.8	0
72	Abstract B130: Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy. , 2016, , .		0

#	Article	IF	Citations
73	Abstract 742: A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice. , 2016, , .		0
74	Abstract A045: Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine. , 2016, , .		0
75	Abstract A046: Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery. , 2016, , .		0
76	Abstract 1198: Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients. , 2019, , .		0
77	Identification of neoantigens as potential vaccines in hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S634-S635.	1.8	0
78	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
79	Abstract 1198: Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients. , 2019, , .		0